EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH
(EEJSAR) ISSN: 2992-4146
©EEJSAR Publications Volume 7 Issue 3 2025

Neonatal Immune System Plasticity: Implications for Immunotherapy and Vaccine-Induced Programming

Gakire Munyaneza H.

Faculty of Engineering Kampala International University Uganda

ABSTRACT

The neonatal period represents a critical window of immune system development marked by profound plasticity and adaptability. Unlike the relatively mature adult immune system, the neonatal immune landscape is characterized by a delicate balance between tolerance and responsiveness, allowing for the establishment of immune homeostasis while limiting deleterious inflammation. This review explores the unique features of neonatal immune system plasticity, including cellular and molecular components that govern its development, and how these characteristics influence responses to immunotherapeutic interventions and early-life vaccination. We discuss recent advances in understanding innate and adaptive immune programming in neonates, the role of microbial colonization, maternal immunity, and epigenetic regulation. Furthermore, we examine how targeted immunotherapies and vaccines administered in early life can leverage this plasticity to induce long-term immune outcomes, including disease protection and potential immune tolerance. Special attention is given to novel strategies such as adjuvant optimization, mRNA platforms, and immune modulators tailored to neonatal immunity. Finally, we address the ethical and translational challenges associated with immunological interventions during this vulnerable period, underscoring the need for age-specific immunotherapeutic designs and robust safety monitoring frameworks.

Keywords: Neonatal immunity, Immune plasticity, Vaccine programming, Early-life immunotherapy, Immune development

INTRODUCTION

The neonatal immune system is a dynamic and malleable entity undergoing rapid development and refinement during the first weeks of life [1]. Far from being merely immature, it is increasingly recognized as a uniquely adaptable system, shaped by a confluence of genetic, developmental, environmental, and epigenetic influences [2]. This period is marked by a complex interplay between the need to tolerate commensal microbes and maternal antigens, and the imperative to mount protective responses against pathogens [3]. As such, the neonatal immune system has evolved a specialized balance that prioritizes regulation and tissue preservation over robust inflammation [4]. Historically, neonatal immunity was viewed as deficient or underdeveloped, with an emphasis on its limitations, such as reduced antigen presentation, weaker inflammatory responses, and impaired memory formation [5]. However, recent advances in immunology have reframed this perspective, highlighting the inherent plasticity of neonatal immune cells, particularly their capacity to be programmed or "educated" by early-life exposures [6]. This plasticity encompasses the ability of both innate and adaptive immune compartments to respond to environmental cues—including microbial colonization, maternal antibodies, and nutritional factors with enduring consequences for immune function across the lifespan [7]. Importantly, this heightened plasticity renders the neonatal period a critical window of opportunity for immunomodulatory interventions. Immunotherapies and vaccines administered during this phase have the potential not only to protect against immediate threats but also to influence the trajectory of immune development and disease susceptibility later in life [8]. At the same time, this sensitivity to modulation raises concerns about unintended long-term effects, such as immune tolerance, hypersensitivity, or autoimmune risk [9]. As such, understanding the mechanisms that underlie neonatal immune plasticity is essential for designing age-

appropriate interventions that are both effective and safe. This review aims to explore the current knowledge on neonatal immune system plasticity and its implications for immunotherapy and vaccine-induced programming.

Developmental Plasticity of the Neonatal Immune System

The neonatal immune system is not a miniature version of the adult immune system but rather a unique and transitional system with remarkable plasticity [7]. This plasticity allows for rapid adaptation to environmental exposures while maintaining a controlled immunological balance. During this early phase of life, immune responses are tightly regulated to avoid damaging inflammation that could interfere with organogenesis and tissue remodeling [10. The architecture and functionality of both innate and adaptive immunity in neonates are specialized to meet the dual demands of tolerance to non-harmful antigens and protection against pathogens.

Innate Immunity

Innate immunity in neonates forms the frontline defense against infections and is essential for shaping adaptive responses [11[. However, neonatal innate immune responses are often biased toward anti-inflammatory and tolerogenic outcomes. This is partly attributed to altered functionality of key innate cells, including dendritic cells (DCs), macrophages, neutrophils, and natural killer (NK) cells. Dendritic cells in neonates display reduced expression of co-stimulatory molecules and decreased antigen-presenting capacity, which leads to suboptimal T cell activation [12]. Neonatal macrophages exhibit diminished phagocytic activity and altered cytokine secretion, with a preference for interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), both of which promote immune regulation. Neutrophils in neonates have impaired chemotaxis, reduced reactive oxygen species (ROS) production, and delayed apoptosis, which may limit their bactericidal capacity but prolong their presence at sites of infection [13]. Toll-like receptor (TLR) signaling pathways, critical for pathogen recognition, are present but functionally attenuated in neonates. For instance, TLR4-mediated responses to lipopolysaccharide (LPS) result in reduced pro-inflammatory cytokine production. Despite these limitations, neonatal innate immunity can be effectively activated under the right conditions [14]. Mucosal tissues, such as the gastrointestinal and respiratory tracts, exhibit heightened innate responses to microbial colonization, suggesting tissue-specific adaptation and responsiveness. Moreover, evidence supports the concept of "trained immunity," whereby innate cells undergo functional reprogramming following early microbial or vaccine exposure, resulting in enhanced responses to subsequent infections [15].

Adaptive Immunity

The adaptive immune system in neonates is characterized by a distinct composition and functional profile that differs significantly from that of older children and adults. T and B lymphocytes are present in adequate numbers but exhibit unique phenotypic and functional characteristics due to their recent emergence from primary lymphoid organs [16]. Neonatal T cells are predominantly recent thymic emigrants with a high expression of surface markers such as CD31 and a bias toward Th2 and regulatory phenotypes [17]. This skewing limit pro-inflammatory Th1 responses, which could be harmful during early development, but also compromises responses to intracellular pathogens. Regulatory T cells (Tregs) are more prevalent in neonates and play a critical role in establishing tolerance to maternal antigens, self-antigens, and commensal microbiota [18]. The humoral arm of adaptive immunity is similarly specialized. B cell repertoires in neonates are more restricted, with reduced somatic hypermutation and limited class-switch recombination. As a result, antibodies produced are often of lower affinity and predominantly of the IgM isotype [19]. However, neonatal B cells can respond effectively to T-independent antigens, such as polysaccharides, and demonstrate considerable plasticity upon priming. Importantly, memory B cell formation and long-lived plasma cell differentiation are possible with appropriate antigenic stimulation, particularly when adjuvants or booster strategies are employed [20]. The plasticity of neonatal adaptive immunity offers opportunities for targeted vaccine and immunotherapy design. Recent studies have demonstrated that early-life immunization can prime robust and durable memory responses, especially when combined with adjuvants that are specifically tailored to overcome neonatal immune constraints [7]. In summary, the neonatal immune system possesses a high degree of developmental plasticity, balancing tolerance and protection through a tightly regulated interplay of innate and adaptive components. This unique immunological landscape provides both challenges and opportunities for designing interventions that optimize immune programming and long-term health.

Immunotherapeutic Opportunities in Early Life

The neonatal period offers a unique and promising window for immunotherapeutic interventions due to the heightened plasticity and responsiveness of the developing immune system [21]. Strategic immune modulation during this stage can not only confer immediate protection but also shape long-term immunity and disease susceptibility [22] Advances in immunology and biotechnology are now making it possible to tailor immunotherapies specifically for neonatal immune profiles.

Early-Life Vaccination Strategies

Vaccination during the neonatal period has the potential to induce robust and durable immunity when carefully designed to align with the unique features of the neonatal immune system [23] Traditional vaccines often underperform in neonates due to low immunogenicity, but innovative strategies are addressing this challenge. Neonatal-specific adjuvants, such as Toll-like receptor (TLR) 7/8 agonists, have shown promise in enhancing both innate and adaptive responses. Novel delivery platforms, including lipid nanoparticles and mRNA-based vaccines, offer improved antigen presentation and immunogenicity tailored to early-life physiology [24]. Mucosal immunization approaches are also gaining interest, as they exploit the highly active mucosal surfaces in neonates for both local and systemic immunity [25]. Crucially, the timing, dosing, and antigen design must be optimized to stimulate protective immunity without triggering harmful inflammation or immune dysregulation.

Immune Modulators and Biologics

In addition to vaccines, biologic therapies and immune modulators are increasingly being explored for neonatal use [26]. Monoclonal antibodies, such as palivizumab for respiratory syncytial virus (RSV), are already clinically applied in newborns. Experimental therapies include cytokine-based treatments, tolerogenic dendritic cell transfer, and epigenetic modulators aimed at preventing autoimmunity or chronic inflammation [27]. These approaches can correct congenital immune defects or support immune function during critical periods of vulnerability.

Trained Immunity and Immune Memory

The concept of trained immunity refers to the functional reprogramming of innate immune cells through early exposures, leading to enhanced responses to subsequent infections [28]. The BCG vaccine exemplifies this phenomenon, offering non-specific protection against a variety of pathogens [29]. Understanding and harnessing trained immunity may enable broad-spectrum immunoprophylaxis in neonates, particularly in settings with high infectious disease burdens.

Long-Term Implications of Early-Life Immunomodulation

Early-life immunomodulation offers the potential to profoundly shape immune development and long-term health outcomes [30]. However, the long-term consequences of these interventions must be carefully evaluated to ensure that benefits outweigh risks. The plasticity of the neonatal immune system, while advantageous for adaptive programming, also renders it susceptible to maladaptive imprinting if interventions are improperly timed or overly aggressive [31].

Risk of Immune Dysregulation

One of the major concerns associated with neonatal immunotherapy is the risk of immune dysregulation [27. Inappropriate modulation of the immune system during critical windows of development may predispose individuals to adverse outcomes such as allergic diseases, autoimmunity, or chronic inflammatory conditions [32]. For instance, excessive skewing toward Th2 responses may promote allergic sensitization, while insufficient regulatory signaling could fail to prevent autoimmune reactivity [33]. Similarly, early exposure to potent adjuvants or immune stimulants could disrupt the natural development of tolerance to self and environmental antigens. Therefore, rigorous preclinical safety testing, long-term surveillance, and age-specific risk assessment are essential components of neonatal immunotherapy development.

Lifespan Immunity and Disease Prevention

Conversely, well-designed neonatal immunotherapies can offer enduring benefits by directing immune maturation toward balanced, protective profiles. Early immune imprinting can reduce susceptibility to infectious diseases, modulate inflammatory pathways, and potentially lower the lifetime risk of non-communicable diseases such as asthma, type 1 diabetes, and certain cancers [34]. For example, early BCG vaccination has been associated with lower all-cause mortality and reduced incidence of respiratory infections, effects thought to be mediated through trained immunity [35]. Identifying optimal windows of intervention—when the immune system is most amenable to beneficial programming is critical to achieving these long-term outcomes [36]. Ultimately, integrating immunological insights with developmental biology will be key to unlocking the full preventive potential of neonatal immunotherapies.

CONCLUSION

Advancing neonatal immunotherapy requires an integrated approach that combines immunology, vaccinology, systems biology, and bioethics. With ongoing advances in immune profiling and precision medicine, there is an unprecedented opportunity to harness neonatal immune plasticity for tailored, safe, and effective interventions that extend benefits across the lifespan.

REFERENCES

1. Moraes-Pinto MI, Suano-Souza F, Aranda CS. Immune system: development and acquisition of immunological competence. J Pediatr (Rio J). 2021 Mar-Apr;97 Suppl 1(Suppl 1):S59-S66. doi: 10.1016/j.jped.2020.10.006. Epub 2020 Nov 9. PMID: 33181111; PMCID: PMC9432342.
2. Nunez N, Réot L, Menu E. Neonatal Immune System Ontogeny: The Role of Maternal Microbiota and Associated Factors. How Might the Non-Human Primate Model Enlighten the Path? Vaccines (Basel). 2021 Jun 1;9(6):584. doi: 10.3390/vaccines9060584. PMID: 34206053; PMCID: PMC8230289.
3. Sedney CJ, Harvill ET. The Neonatal Immune System and Respiratory Pathogens. *Microorganisms*. 2023; 11(6):1597. https://doi.org/10.3390/microorganisms11061597
4. Li, J., Xiao, C., Li, C. *et al.* Tissue-resident immune cells: from defining characteristics to roles in diseases. *Sig Transduct Target Ther* **10**, 12 (2025). https://doi.org/10.1038/s41392-024-02050-5
5. Zhang, F., Xia, Y., Su, J. *et al.* Neutrophil diversity and function in health and disease. *Sig Transduct Target Ther* **9**, 343 (2024). https://doi.org/10.1038/s41392-024-02049-y
6. Mititelu M, Lupuliasa D, Neacşu SM, Olteanu G, Busnatu ŞS, Mihai A, Popovici V, Măru N, Boroghină SC, Mihai S, et al. Polyunsaturated Fatty Acids and Human Health: A Key to Modern Nutritional Balance in Association with Polyphenolic Compounds from Food Sources. *Foods*. 2025; 14(1):46. https://doi.org/10.3390/foods14010046
7. Tsafaras GP, Ntontsi P, Xanthou G. Advantages and Limitations of the Neonatal Immune System. Front Pediatr. 2020 Jan 28;8:5. doi: 10.3389/fped.2020.00005. PMID: 32047730; PMCID: PMC6997472.
8. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol. 2014 Sep;10(9):1171-84. doi: 10.1586/1744666X.2014.942288. Epub 2014 Aug 4. PMID: 25088080; PMCID: PMC4407563.
9. Maheshwari, A., La Gamma, E.F. (2018). Fundamentals of Feto-Neonatal Immunology. In: Buonocore, G., Bracci, R., Weindling, M. (eds) Neonatology. Springer, Cham. https://doi.org/10.1007/978-3-319-29489-6_246
10. PrabhuDas, M., Adkins, B., Gans, H. *et al.* Challenges in infant immunity: implications for responses to infection and vaccines. *Nat Immunol* **12**, 189–194 (2011). https://doi.org/10.1038/ni0311-189
11. Crofts KF, Alexander-Miller MA. Challenges for the Newborn Immune Response to Respiratory Virus Infection and Vaccination. *Vaccines*. 2020; 8(4):558. https://doi.org/10.3390/vaccines8040558
12. Rueda CM, Moreno-Fernandez ME, Jackson CM, Kallapur SG, Jobe AH, Chougnet CA. Neonatal regulatory T cells have reduced capacity to suppress dendritic cell function. Eur J Immunol. 2015 Sep;45(9):2582-92. doi: 10.1002/eji.201445371. Epub 2015 Jun 25. PMID: 26046326; PMCID: PMC4666291.
13. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert Rev Clin Immunol. 2014 Sep;10(9):1171-84. doi: 10.1586/1744666X.2014.942288. Epub 2014 Aug 4. PMID: 25088080; PMCID: PMC4407563.
14. Kurilin V, Alshevskaya A, Sennikov S. Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases. *Biomedicines*. 2024; 12(3):699. https://doi.org/10.3390/biomedicines12030699
15. Wang, YT., Branche, E., Xie, J. *et al.* Zika but not Dengue virus infection limits NF-κB activity in human monocyte-derived dendritic cells and suppresses their ability to activate T cells. *Nat Commun* **16**, 2695 (2025). https://doi.org/10.1038/s41467-025-57977-2
16. Lambrecht, B.N. Immunologists getting nervous: neuropeptides, dendritic cells and T cell activation. *Respir Res* **2**, 133 (2001). https://doi.org/10.1186/rr49
17. Fike AJ, Kumova OK, Carey AJ. Dissecting the defects in the neonatal CD8$^+$ T-cell response. J Leukoc Biol. 2019 Nov;106(5):1051-1061. doi: 10.1002/JLB.5RU0319-105R. Epub 2019 Jul 1. PMID: 31260598; PMCID: PMC6803028.
18. Zens, K.D., Connors, T. & Farber, D.L. Tissue compartmentalization of T cell responses during early life. *Semin Immunopathol* **39**, 593–604 (2017). https://doi.org/10.1007/s00281-017-0648-7
19. Vogel, K., Pierau, M., Arra, A. *et al.* Developmental induction of human T-cell responses against *Candida albicans* and *Aspergillus fumigatus*. *Sci Rep* **8**, 16904 (2018). https://doi.org/10.1038/s41598-018-35161-5
20. Maheshwari, A., La Gamma, E.F. (2017). Fundamentals of Feto-Neonatal Immunology. In: Buonocore, G., Bracci, R., Weindling, M. (eds) Neonatology. Springer, Cham. https://doi.org/10.1007/978-3-319-18159-2_246-1

21. Moraes-Pinto MI, Suano-Souza F, Aranda CS. Immune system: development and acquisition of immunological competence. J Pediatr (Rio J). 2021 Mar-Apr;97 Suppl 1(Suppl 1):S59-S66. doi: 10.1016/j.jped.2020.10.006. Epub 2020 Nov 9. PMID: 33181111; PMCID: PMC9432342.
22. Futata EA, Fusaro AE, de Brito CA, Sato MN. The neonatal immune system: immunomodulation of infections in early life. Expert Rev Anti Infect Ther. 2012 Mar;10(3):289-98. doi: 10.1586/eri.12.9. PMID: 22397563.
23. Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. *Cell Res* **30**, 492–506 (2020). https://doi.org/10.1038/s41422-020-0332-7
24. Hu, Y., Hu, Q., Li, Y. *et al.* γδ T cells: origin and fate, subsets, diseases and immunotherapy. *Sig Transduct Target Ther* **8**, 434 (2023). https://doi.org/10.1038/s41392-023-01653-8
25. Zhao R-J, Fan X-X. Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy. *International Journal of Molecular Sciences.* 2025; 26(4):1440. https://doi.org/10.3390/ijms26041440
26. 26 Schüller SS, Kramer BW, Villamor E, Spittler A, Berger A, Levy O. Immunomodulation to Prevent or Treat Neonatal Sepsis: Past, Present, and Future. Front Pediatr. 2018 Jul 19;6:199. doi: 10.3389/fped.2018.00199. PMID: 30073156; PMCID: PMC6060673.
27. Malhotra A, Thebaud B, Paton MCB, Fleiss B, Papagianis P, Baker E, Bennet L, Yawno T, Elwood N, Campbell B, Chand K, Zhou L, Penny T, Nguyen T, Pepe S, Gunn AJ, McDonald CA. Advances in neonatal cell therapies: Proceedings of the First Neonatal Cell Therapies Symposium (2022). Pediatr Res. 2023 Nov;94(5):1631-1638. doi: 10.1038/s41390-023-02707-x. Epub 2023 Jun 28. PMID: 37380752; PMCID: PMC10624618.
28. Paton, M.C.B., Benders, M., Blatch-Williams, R. *et al.* Updates on neonatal cell and novel therapeutics: Proceedings of the Second Neonatal Cell Therapies Symposium (2024). *Pediatr Res* (2025). https://doi.org/10.1038/s41390-025-03856-x
29. Pyzik, M., Kozicky, L.K., Gandhi, A.K. *et al.* The therapeutic age of the neonatal Fc receptor. *Nat Rev Immunol* **23**, 415–432 (2023). https://doi.org/10.1038/s41577-022-00821-1
30. Alenzi F, P. D'Cruz D. Recent Advances in SLE Treatment Including Biologic Therapies [Internet]. Systemic Lupus Erythematosus - Pathogenesis and Management. IntechOpen; 2023. Available from: http://dx.doi.org/10.5772/intechopen.105558
31. Tsafaras GP, Ntontsi P, Xanthou G. Advantages and Limitations of the Neonatal Immune System. Front Pediatr. 2020 Jan 28;8:5. doi: 10.3389/fped.2020.00005. PMID: 32047730; PMCID: PMC6997472.
32. Sullivan G, Galdi P, Borbye-Lorenzen N, Stoye DQ, Lamb GJ, Evans MJ, Skogstrand K, Chandran S, Boardman JP. Preterm Birth Is Associated With Immune Dysregulation Which Persists in Infants Exposed to Histologic Chorioamnionitis. Front Immunol. 2021 Aug 27;12:722489. doi: 10.3389/fimmu.2021.722489. PMID: 34512648; PMCID: PMC8430209.
33. Li, Y., Yang, S., Wang, G. *et al.* Effects of immunotherapy on mortality in neonates with suspected or proven sepsis: a systematic review and network meta-analysis. *BMC Pediatr* **19**, 270 (2019). https://doi.org/10.1186/s12887-019-1609-1
34. Aslam, S., O'Hare, F., Eliwan, H., Molloy, E.J. (2019). Immunology and Immunodeficiencies in Children. In: Puri, P. (eds) Pediatric Surgery. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38482-0_29-2
35. Casagrande S, Sopetto GB, Bertalot G, Bortolotti R, Racanelli V, Caffo O, Giometto B, Berti A, Veccia A. Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations. *Cancers.* 2024; 16(7):1440. https://doi.org/10.3390/cancers16071440
36. Cao, M., Wang, G. & Xie, J. Immune dysregulation in sepsis: experiences, lessons and perspectives. *Cell Death Discov.* **9**, 465 (2023). https://doi.org/10.1038/s41420-023-01766-7

CITE AS: Gakire Munyaneza H. (2025). Neonatal Immune System Plasticity: Implications for Immunotherapy and Vaccine-Induced Programming. EURASIAN EXPERIMENT JOURNAL OF SCIENTIFIC AND APPLIED RESEARCH, 7(3):71-75